Optomed Q2: Soft sales and important quarters ahead - Redeye

Redeye provides an update following Optomed’s Q2 report. Although sales and EBIT came in lower than anticipated, we argue that the investment case remains intact. We highlight upcoming reports that may potentially show sales related to the US rollout of Aurora AEYE. Furthermore, we have made only minor estimate changes, leaving the fair value range unchanged.

Länk till analysen i sin helhet: https://www.redeye.se/research/1028439/optomed-q2-soft-sales-and-important-quarters-ahead?utm_source=finwire&utm_medium=RSS